Phase I/II clinical trial of modified vaccinia virus Ankara (MVA) [TBC-MVA; smallpox vaccine; Therion Biologics] to evaluate its safety, immunogenicity and protective efficacy against Dryvax [smallpox vaccine] challenge in vaccinia-immune individuals
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Modified vaccinia Ankara (Primary)
- Indications Smallpox
- Focus Adverse reactions
- 08 Mar 2007 Status change from in progress to completed.
- 09 Feb 2007 Results have been reported.
- 08 Dec 2005 New trial record.